Ken Griffin Kinnate Biopharma Inc. Transaction History

Citadel Advisors LLC

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$2.24 - $2.66 $450,638 - $535,133	-201,178 Reduced 48.38%	214,664 $571,000
Q4 2023 Feb 14, 2024	SELL	$1.07 - $2.5 $689,081 - $1.61 Million	-644,001 Reduced 60.76%	415,842 $985,000
Q3 2023 Nov 14, 2023	SELL	$1.38 - $3.31 $36,629 - $87,857	-26,543 Reduced 2.44%	1,059,843 $1.48 Million
Q2 2023 Aug 14, 2023	BUY	$2.33 - $6.84 $29,910 - $87,805	12,837 Added 1.2%	1,086,386 $3.29 Million
Q1 2023 May 15, 2023	SELL	$3.46 - $7.98 $103,194 - $238,003	-29,825 Reduced 2.7%	1,073,549 $6.71 Million
Q4 2022 Feb 14, 2023	BUY	$5.26 - $12.19 $37,203 - $86,219	7,073 Added 0.65%	1,103,374 $6.73 Million
Q3 2022 Nov 14, 2022	SELL	$9.86 - $15.76 $306,527 - $489,946	-31,088 Reduced 2.76%	1,096,301 $13.1 Million
Q2 2022 Aug 15, 2022	SELL	$7.43 - $13.0 $42,090 - $73,645	-5,665 Reduced 0.5%	1,127,389 $14.2 Million
Q1 2022 May 16, 2022	BUY	$7.73 - $17.99 $87,735 - $204,186	11,350 Added 1.01%	1,133,054 $12.8 Million
Q4 2021 Feb 14, 2022	SELL	$16.5 - $25.48 $537,388 - $829,858	-32,569 Reduced 2.82%	1,121,704 $19.9 Million
Q3 2021 Nov 15, 2021	SELL	$17.81 - $24.87 $2.61 Million - $3.65 Million	-146,614 Reduced 11.27%	1,154,273 $26.6 Million
Q2 2021 Aug 16, 2021	SELL	$22.19 - $31.55 $327,590 - $465,772	-14,763 Reduced 1.12%	1,300,887 $30.3 Million
Q1 2021 May 17, 2021	BUY	$26.99 - $40.0 $4,048 - $6,000	150 Added 0.01%	1,315,650 $41 Million
Q4 2020 Feb 16, 2021	BUY	$36.35 - $45.25 $47.8 Million - $59.5 Million	1,315,500 New	1,315,500 $52.3 Million

292K

Ticker KNTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,145,600
Description
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.